21585-16-0

Basic information

• Product Name: 2,3-dihydro-5-(2-hydroxyethyl)-6-methyl-2-thioxo-1H-pyrimidin-4-one
• Synonyms: 2,3-dihydro-5-(2-hydroxyethyl)-6-methyl-2-thioxo-1H-pyrimidin-4-one;2,3-Dihydro-5-(2-hydroxyethyl)-6-methyl-2-thioxopyrimidin-4(1H)-one;5-(2-hydroxyethyl)-6-methyl-2-thioxo-2,3-dihydropyrimidin-4(1H)-one;5-(2-hydroxyethyl)-6-methyl-2-sulfanylidene-1H-pyrimidin-4-one
• CAS NO: 21585-16-0
• Molecular Formula: C₇H₁₀N₂O₂S
• Molecular Weight: 186.2315
• EINECS: 244-460-2
• Mol File: 21585-16-0.mol
• Article Data: 3

Chemical Properties

• Melting Point: 270℃
• Boiling Point: 424°Cat760mmHg
• Flash Point: 210.3°C
• Appearance: /
• Density: 1.38g/cm³
• Vapor Pressure: 6.01E-08mmHg at 25°C
• Refractive Index: 1.631
• CAS DataBase Reference: 2,3-dihydro-5-(2-hydroxyethyl)-6-methyl-2-thioxo-1H-pyrimidin-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-dihydro-5-(2-hydroxyethyl)-6-methyl-2-thioxo-1H-pyrimidin-4-one(21585-16-0)
• EPA Substance Registry System: 2,3-dihydro-5-(2-hydroxyethyl)-6-methyl-2-thioxo-1H-pyrimidin-4-one(21585-16-0)

Safety Data

• Hazardous Substances Data: 21585-16-0(Hazardous Substances Data)

Usage

General Description

2,3-dihydro-5-(2-hydroxyethyl)-6-methyl-2-thioxo-1H-pyrimidin-4-one, also known as Allopurinol, is a medication primarily used to treat gout and certain types of kidney stones. It works by decreasing the production of uric acid in the body, which can help prevent crystals from forming and causing pain and inflammation. Allopurinol is classified as a xanthine oxidase inhibitor and is often prescribed for patients who have high levels of uric acid in their blood or have had previous issues with gout or kidney stones. It is generally taken orally and its effects can be seen within a few weeks of starting treatment. Common side effects may include skin rash, diarrhea, and drowsiness, and it is important for patients to be monitored regularly by a healthcare provider while taking this medication.

InChI:InChI=1/C7H10N2O2S/c1-4-5(2-3-10)6(11)9-7(12)8-4/h10H,2-3H2,1H3,(H2,8,9,11,12)

Upstream product

• 517-23-7 3-acetyl-2-oxo-4,5-dihydrofuran 
• 17356-08-0 thiourea 
• 86351-01-1 2-(2-hydroxy-ethyl)-acetoacetic acid ethyl ester 

Downstream Products

• 98489-83-9 5-(2-hydroxyethyl)-6-methyl-2-methylthiopyrimidin-4(3H)-one 
• 23935-66-2 5-(2-hydroxyethyl)-6-methyluracil 
• 86487-53-8 2,3-dihydro-6-(2-hydroxyethyl)-7-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one 
• 78831-52-4 2-<5-(1,2,3,4-tetrahydro-6-methyl-2,4-dioxopyrimidinyl)>ethanethiol 
• 178268-48-9 7-(4-Fluoro-phenyl)-4-methyl-2-methylsulfanyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine 
• 74187-94-3 2-Hydrazino-5-(2-hydroxy-ethyl)-6-methyl-3H-pyrimidin-4-one 
• 78831-58-0 2-(4-Methyl-5,6-dihydro-furo[2,3-d]pyrimidin-2-yl)-isothiourea; hydrobromide 
• 78831-51-3 2-<5-(1,2,3,4-tetrahydro-6-methyl-2,4-dioxopyrimidinyl)>ethylthiouronium bromide 

Relevant articles and documents

Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites

The present invention relates to a group of novel tetrahydropyridin-4-yl indoles with a dual mode of action: serotonin reuptake inhibition and affinity for dopamine-D2 receptors, to methods for the preparation of these compounds and to novel intermediates useful for the synthesis of said tetrahydropyridin-4-yl indoles. The invention also relates to the use of a compound disclosed herein for the manufacture of a medicament giving a beneficial effect. The invention relates to novel tetrahydropyridin-4-yl indoles of the formula. and tautomers, stereoisomers, prodrugs, N-oxides, pharmacologically acceptable salts, hydrates and solvates thereof, wherein: R1 is hydrogen, halogen, alkyl(C1-3) or alkoxy(C1-3), CN or CF3, R2 is hydrogen or alkyl(C1-3), R3 is hydrogen or alkyl(C1-3), Z is hydrogen or alkyl(C1-3), alkoxy(C1-3) or alkylthio(C1-3), A is hydrogen or alkyl(C1-3), or A and Z together form a saturated or (partly) unsaturated 5- or 6-membered ring which may be substituted with halogen, alkyl (C1-3) or phenyl, in which ring Z represents carbon, sulfur of nitrogen.

Synthesis and in vitro evaluation of some new pyrimidines and related condensed ring systems as potential anticancer agents

Several new pyrimidines 6-11, 18-20, furo-, thieno-, and pyrrolo[2,3-d]pyrimidines 3, 8, 12, triazolo[4,3-a]pyrimidines 14, 15, 16 and tetrazolo[1,5-a]pyrimidine 17 were prepared from the known intermediate 5-(2-hydroxyethyl)-6-methyl-2-thiouracil (2). Compound 7 (4-chloro-5-(2-chloroethyl)-2-methylthio-6-methyl-pyrimidine) exhibited weak antitumor activity in vitro.